Autores
Javier Cortes, David W Cescon, Hope S Rugo, Zbigniew Nowecki, Seock-Ah Im, Mastura Md Yusof, Carlos Gallardo, Oleg Lipatov, Carlos H Barrios, Esther Holgado, Hiroji Iwata, Norikazu Masuda, Marco Torregroza Otero, Erhan Gokmen, Sherene Loi, Zifang Guo, Jing Zhao, Gursel Aktan, Vassiliki Karantza, Peter Schmid, Fein Luis, Gomez Abuin Gonzalo, Kaen Diego, Kowalwszyn Ruben, Molina Matias, Varela Mirta, Baron-Hay Sally, Begbie Stephen, Clingan Philip, Loi Sherene, Sabanathan Dhanusha, Gombos Andrea, Taylor Donatienne, Barrios Carlos, Brust Leandro, Costa Fabiano, Hegg Roberto, Lacerda Domicio Carvalho, Lissa Fernando Cezar Toniazzi, Rocha Roberto Odebrecht, Scalabrini Neto Antonio Orlando, Silva Felipe, Cescon David, Charpentier Danielle, Ferrario Cristiano, Song Xinni, Yu Joanne, Acevedo Alejandro, Gallardo Carlos, Salas Claudio, Sanchez Cesar, Yanez Eduardo, Gomez Diaz Alvaro, Sanchez Jesus, Holeckova Petra, Kral Zdenek, Melichar Bohuslav, Petrakova Katarina, Prausova Jana, Glavicic Vesna, Jakobsen Erik, Jensen Jeanette, Linnet Soren, Lorincz Tamas, Bonnefoi Herve, Desmoulins Isabelle, Goncalves Anthony, Hardy-Bessard Anne-Claire, Teixeira Luis, Blohmer Jens-Uwe, Fasching Peter, Forstmeyer Dirk, Harbeck Nadia, Huober Jens, Kaczerowsky Flores de Sousa Anna, Kurbacher Christian, Loibl Sibylle, Lueftner Diana, Park-Simon Tjoung-Won, Schumann Raquel Von, Wimberger Pauline, Chow Louis, Kwong Ava, Ngan Kai Cheong Roger, Arkosy Peter, Csoszi Tibor, Kahan Zsuzsanna, Landherr Laszlo, Mahr Karoly, Rubovszky Gabor, Crown John, Kelly Catherine, Cinieri Saverio, DAlessio Antonietta, Ricevuto Enrico, Aruga Tomoyuki, Fujii Takaaki, Inoue Kenichi, Ishikawa Takashi, Ito Yoshinori, Iwasa Tsutomu, Iwata Hiroji, Kosaka Yoshimasa, Matsumoto Koji, Miyoshi Yasuo, Mukai Hirofumi, Nakamura Seigo, Niikura Naoki, Ohtani Shoichiro, Osaki Akihiko, Sagara Yasuaki, Suzuki Eiji, Takahashi Masato, Tanabe Yuko, Tamura Kenji, Tsugawa Koichiro, Watanabe Junichiro, Yamamoto Naohito, Yamamoto Yutaka, Yamauchi Teruo, Bustam Anita, Md Yusof Mastura, Gomez Villanueva Angel, Juarez Ramiro Alejandro, Martinez Rodriguez Jorge, Morales-Vasquez Flavia, Reyes Contreras Jessica, Beelen Karin, Tjan-Heijnen Vivianne, Porter David, Chmielowska Ewa, Nowakowska-Zajdel Ewa, Nowecki Zbigniew, Radecka Barbara, Streb Joanna, Szczylik Cezary, Tarnawski Rafal, Zurawski Bogdan, Arkhipov Alexander, Fadeeva Natalia, Lipatov Oleg, Meshcheryakov Andrey, Moiseyenko Vladimir, Mukhametshina Guzel, Ahn Jin Hee, Im Seock-Ah, Lee Keun Seok, Park Kwong Hwa, Park Yeon Hee, Bermejo de las Heras Begona
Fecha de publicación
2020/12/5
Revista
The Lancet
Volumen
396
Número
10265
Páginas
1817-1828
Editor
Elsevier
Descripción
Background
Pembrolizumab monotherapy showed durable antitumour activity and manageable safety in patients with metastatic triple-negative breast cancer. We aimed to examine whether the addition of pembrolizumab would enhance the antitumour activity of chemotherapy in patients with metastatic triple-negative breast cancer.
Methods
In this randomised, placebo-controlled, double-blind, phase 3 trial, done in 209 sites in 29 countries, we randomly assigned patients 2:1 with untreated locally recurrent inoperable or metastatic triple-negative breast cancer using a block method (block size of six) and an interactive voice-response system with integrated web-response to pembrolizumab (200 mg) every 3 weeks plus chemotherapy (nab-paclitaxel; paclitaxel; or gemcitabine plus carboplatin) or placebo plus chemotherapy. Randomisation was stratified by type of on-study chemotherapy (taxane or gemcitabine …
Citas totales
Artículos de Google Académico
J Cortes, DW Cescon, HS Rugo, Z Nowecki, SA Im… - The Lancet, 2020